

Patient Satisfaction with Intravenous Omadacycline as a Treatment for Hidradenitis Suppurativa

Peter Y. Ch'en, BS, McCall E. Torpey, BS, Avigdor Nosrati, BS, Michelle Toker, BS, Kristina L. Campton, MD, Steven R. Cohen, MD, MPH
Division of Dermatology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA

BACKGROUND

Why is this study needed?

Hidradenitis suppurativa (HS) is a chronic debilitating skin disorder of follicular biology that is often exacerbated by the presence of microbial organisms. Omadacycline (OMCN) is a broad-spectrum tetracycline used for acute bacterial skin and skin structure infections (ABSSSI).

While oral antibiotics are generally accepted as a core therapy for HS, we explored the use of intravenous (IV) OMCN as a potential new tool in the HS treatment arsenal.

OBJECTIVE

To investigate patient satisfaction, perceived efficacy, and overall experience regarding IV/OMCN for HS.

METHODS

We conducted an IRB-approved retrospective chart review and telephone surveys of 8 patients who received IV/OMCN, 100 mg daily, exclusively following 12-16 weeks of IV ertapenem for highly advanced disease. All participants were undergoing care at the Einstein/Montefiore HS Center between 2020 and 2021.

Medical records provided demographic information. Telephone surveys were designed to characterize the patient experience while on omadacycline and after treatment.

RESULTS


What our study shows:

The average age of participants was 36.8 ± 9.0 years; 6 were female (75.0%). All but one participant (87.5%) were willing to receive IV/OMCN again. At the midpoint (2.5 weeks), dramatic improvement in HS severity was reported as $4.1/5 \pm 0.8$, 5 maximum. Improvement was initially perceptible after 1.3 ± 0.5 weeks; greatest improvement occurred at 2.8 ± 1.8 weeks. The mean maximum improvement was recorded as $83.0\% \pm 17.1\%$ compared to baseline. At the conclusion of treatment, the mean reduction in HS severity was $4.4/5 \pm 0.9$, 5 maximum. Minor adverse events were described by 3 (38.5%) participants, including drowsiness (n=1), nausea (n=1), and diarrhea (n=1).

Table 1. Survey Questions and Results

Question	Response, $\bar{x} \pm SD$
How satisfied are you regarding your overall experience with omadacycline? (1-5, 5 being very satisfied)	4.3 ± 1.2
Think back the midpoint of your most recent omadacycline course. Rate the severity of your HS compared to before treatment (1-5, 5 being much better).	4.1 ± 0.83
How many weeks did it take for you to see any improvements/response to treatment?	1.3 ± 0.5
How many weeks did it take for you to achieve maximum improvement on omadacycline?	2.8 ± 1.8
How would you rate your maximum improvement, ranging from 0% (no improvement) to 100% (no active disease)?	$83.1\% \pm 17.1\%$
Think back to immediately after you completed omadacycline. Rate the severity of your HS compared to before treatment (1-5, 5 being much better).	4.4 ± 0.9
Did you experience a flare after stopping omadacycline?	6 Y, 2 N
How many weeks (if any) after stopping omadacycline did you flare?	5.3 ± 4.2
Did you experience any of side effects while on omadacycline?	Drowsiness (1), Nausea (1), Diarrhea (1)

Figures 1-3. Survey Results



DISCUSSION

Why is this important?

We found a mean 5-week course of IV/OMCN for HS was associated with a high satisfaction, perceived efficacy and an overall positive experience. In our cohort, IV/OMCN was exclusively utilized after 12-16 weeks of IV ertapenem. Small sample size is a study limitation; however, further studies of OMCN, including oral formulations and IV/OMCN monotherapy (without ertapenem) warrant further investigation in HS management.